Connection

Co-Authors

This is a "connection" page, showing publications co-authored by TERZAH HORTON and STEVEN M KORNBLAU.
Connection Strength

3.313
  1. The effects of sample handling on proteomics assessed by reverse phase protein arrays (RPPA): Functional proteomic profiling in leukemia. J Proteomics. 2021 02 20; 233:104046.
    View in: PubMed
    Score: 0.753
  2. Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial. Cancers (Basel). 2024 Apr 09; 16(8).
    View in: PubMed
    Score: 0.238
  3. Valosin-containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children's Oncology Group. Proteomics Clin Appl. 2023 Nov; 17(6):e2200109.
    View in: PubMed
    Score: 0.225
  4. DNA Damage Response-Related Proteins Are Prognostic for Outcome in Both Adult and Pediatric Acute Myelogenous Leukemia Patients: Samples from Adults and from Children Enrolled in a Children's Oncology Group Study. Int J Mol Sci. 2023 Mar 20; 24(6).
    View in: PubMed
    Score: 0.221
  5. Reverse Phase Protein Array Profiling Identifies Recurrent Protein Expression Patterns of DNA Damage-Related Proteins across Acute and Chronic Leukemia: Samples from Adults and the Children's Oncology Group. Int J Mol Sci. 2023 Mar 13; 24(6).
    View in: PubMed
    Score: 0.221
  6. Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children's Oncology Group study. Haematologica. 2022 10 01; 107(10):2329-2343.
    View in: PubMed
    Score: 0.214
  7. Reverse phase protein arrays in acute leukemia: investigative and methodological challenges. Expert Rev Proteomics. 2021 12; 18(12):1087-1097.
    View in: PubMed
    Score: 0.203
  8. Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-?B subunit RelA. Proteomics Clin Appl. 2022 03; 16(2):e2100072.
    View in: PubMed
    Score: 0.202
  9. Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report. Blood. 2021 02 25; 137(8):1050-1060.
    View in: PubMed
    Score: 0.192
  10. Loss of H3K27 methylation identifies poor outcomes in adult-onset acute leukemia. Clin Epigenetics. 2021 01 28; 13(1):21.
    View in: PubMed
    Score: 0.191
  11. Shining a light on cell signaling in leukemia through proteomics: relevance for the clinic. Expert Rev Proteomics. 2018 07; 15(7):613-622.
    View in: PubMed
    Score: 0.160
  12. Recognition of Recurrent Protein Expression Patterns in Pediatric Acute Myeloid Leukemia Identified New Therapeutic Targets. Mol Cancer Res. 2018 08; 16(8):1275-1286.
    View in: PubMed
    Score: 0.157
  13. Recurrent Patterns of Protein Expression Signatures in Pediatric Acute Lymphoblastic Leukemia: Recognition and Therapeutic Guidance. Mol Cancer Res. 2018 08; 16(8):1263-1274.
    View in: PubMed
    Score: 0.157
  14. Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia. Nat Commun. 2022 05 19; 13(1):2801.
    View in: PubMed
    Score: 0.052
  15. RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation by targeting mitotic exit. Oncotarget. 2020 Jun 23; 11(25):2387-2403.
    View in: PubMed
    Score: 0.046
  16. The mitochondrial peptidase, neurolysin, regulates respiratory chain supercomplex formation and is necessary for AML viability. Sci Transl Med. 2020 04 08; 12(538).
    View in: PubMed
    Score: 0.045
  17. IDENTIFYING CANCER SPECIFIC METABOLIC SIGNATURES USING CONSTRAINT-BASED MODELS. Pac Symp Biocomput. 2017; 22:485-496.
    View in: PubMed
    Score: 0.036
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.